| Identification | Back Directory | [Name]
1-(4,6-dimethylpyrimidin-2-yl)-3-[2-(trifluoromethyl)phenyl]guanidine | [CAS]
303094-67-9 | [Synonyms]
ZINC69391
1-(4,6-dimethylpyrimidin-2-yl)-3-[2-(trifluoromethyl)phenyl]guanidine | [Molecular Formula]
C14H14F3N5 | [MDL Number]
MFCD01975775 | [MOL File]
303094-67-9.mol | [Molecular Weight]
309.29 |
| Chemical Properties | Back Directory | [Melting point ]
149-151 °C | [Boiling point ]
404.3±55.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 25 mg/mL (80.83 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
4.69±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ZINC 69391 is a novel specific Rac1 inhibitor, interferring with the interaction of Rac1 with Dock180, a relevant Rac1 activator in glioma invasion, and to reduce Rac1-GTP levels. | [in vivo]
ZINC69391 (25 mg/kg; i.p; daily for 21 days) impairs metastatic lung colonization in a syngeneic animal model[3]. | Animal Model: | Specific pathogen-free female BALB/c inbred mice (bearing F3II cells)[3] | | Dosage: | 25 mg/kg body weight | | Administration: | I.p; daily for 21 days | | Result: | Significantly reduced by about 60% the formation of total metastatic lung colonies.
|
|
|
|